This study aims to explore the correlation between using ballistocardiography for monitoring respiration and heart rate in neonates under invasive and non-invasive respiratory support.

开始日期2024-09-01

申办/合作机构

辅仁大学

NCT06579872 / Not yet recruitingN/AIIT

Association Between Cardiopulmonary Function, Mobility, Walking Ability, and Plantar Pressure Changes in Patients With Chronic Obstructive Pulmonary Disease: A Case-Control Study

It aims to understand the differences in everyday mobility and activity capabilities among patients with varying disease progression and severity, to serve as reference indicators for evaluating the effectiveness of pulmonary rehabilitation exercise training.

开始日期2024-09-01

申办/合作机构

辅仁大学

NCT06521619 / Active, not recruitingN/AIIT

Analysis of Postoperative Analgesic Effect and Complications Among Different Approaches of Nerve Block for Total Knee Replacement Surgery

This study is a retrospective analysis using the accumulated clinical database from 2017/09-2023/11 to analyze patients who underwent total knee arthroplasty and received nerve blocks. The aim is to compare the analgesic effects, incidence of nerve injury, and rate of chronic pain under different nerve block techniques.

开始日期2024-06-26

申办/合作机构

辅仁大学

100 项与辅仁大学相关的临床结果

登录后查看更多信息

0 项与辅仁大学相关的专利（医药）

登录后查看更多信息

10,582

项与辅仁大学相关的文献（医药）

2025-01-01·Journal of Affective Disorders

The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial

Article

作者: Kuo, Po-Hsiu ; Chiu, Chih-Chiang ; Lin, Chemin ; Chen, Wen-Yin ; Lee, Shwu-Hua ; Cheng, Ying-Chih

BACKGROUNDReports on the efficacy of omega-3 fatty acids (n-3 PUFAs) for the treatment of late-life depression (LLD) are mixed, and most studies focus on the modification of depressive symptoms rather than depression prevention. The aim of the present study was to investigate the efficacy of n-3 PUFAs in preventing depressive recurrence in patients with late-life depression. In addition, we investigated the effects of n-3 PUFAs on changes in depressive and anxiety symptoms and inflammatory markers in LLD.METHODSA 52-week, double-blind, randomized, controlled trial was conducted. We enrolled a total of 39 euthymic patients with LLD. They were randomized to receive either n-3 PUFAs (1.2 g per day of eicosapentaenoic acid and 1 g of docosahexaenoic acid) or placebo for 52 weeks. Recurrence of depression and severity of depression symptoms were assessed at baseline and weeks 4, 8, 16, 24, 32, 40, and 52.RESULTSA total of 39 patients completed the trial with 19 in the n-3 PUFAs group and 20 in the placebo group. Cox proportional hazard regression indicated that n-3 PUFAs had significant protective effect on depression recurrence (Hazard Ratio: 0.295, 95 % Confidence Interval: 0.093-0.931, p value =0.037). But n-3 PUFAs intervention had no significant effect in reducing depressive or anxiety symptoms, inflammatory markers over the placebo group.LIMITATIONThe results should be interpreted with consideration of the modest sample size.CONCLUSIONThese findings suggest that n-3 PUFAs may have a prophylactic effect in currently euthymic patients with LLD.

2024-12-01·Endoscopy

Marking can improve defect closure in endoscopic suturing systems

Article

作者: Fu, Kuang-I ; Chen, Hsin-Yu ; Tsai, Kun-Feng ; Chuah, Yoen-Young ; Lee, Chung-Ying ; Chou, Chu-Kuang ; Toh, Ding-Ek

2024-12-01·European Journal of Cell Biology

Stable laminar shear stress induces G1 cell cycle arrest and autophagy in urothelial carcinoma by a torque sensor-coupled cone-and-plate device

Article

作者: Chung, Chih-Ang ; Cheng, Yu-Che ; Liu, Wei-Hung ; Yu, Tien-Ssu ; Huang, Sheng-Yuan ; Lin, Jiun-Han

The microenvironments of urinary systems play crucial roles in the development and metastasis of cancers due to their generation of complex temporal and spatial fluidic profiles. Because of their versatility in creating desired biomimetic flow, cone-and-plate bioreactors offer great potential for bladder cancer research. In this study, we construct a biocompatible cone-and-plate device coupled with a torque sensor, enabling the application and real-time monitoring of stable shear stress up to 50 dyne/cm². Under a stable shear stress stimulation at 12 dyne/cm², bladder cancer cell BFTC-905 is arrested at the G1 phase with decreased cell proliferation after 24-hour treatment. This effect is associated with increased cyclin-dependent kinase inhibitors p21 and p27, inhibiting cyclin D1/CDK4 complex with dephosphorylation of serine 608 on the retinoblastoma protein. Consequently, an increase in cyclin D3 and decreases in cyclin A2 and cyclin E2 are observed. Moreover, we demonstrate that the shear stress stimulation upregulates the expression of autophagy-related proteins Beclin-1, LC3B-I and LC3B-II, while caspase cleavages are not activated under the same condition. The design of this system and its application shed new light on flow-induced phenomena in the study of urothelial carcinomas.

项与辅仁大学相关的新闻（医药）

2023-06-02

·BioSpace

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She brings a wealth of global executive management, regulatory, and drug approval experience in five therapeutic areas including cancer drug development, during a ~ 30-year tenure at Bristol Myers Squibb Company. TAIPEI, Taiwan, June 02, 2023 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) | Effective immediately, the OBI Pharma Board of Directors have appointed Heidi Wang, Ph.D. as Chief Executive Officer, a position previously held by Chairman and CEO, Yun Yen, MD. “We are excited that Dr. Wang has been appointed CEO of OBI Pharma to bring strategic vision and lead the organization with our innovative cancer therapeutics pipeline, towards successful development and potentially regulatory approvals worldwide. Dr. Wang brings a wealth of global executive management, scientific knowledge, development, and regulatory experience during her ~30 years tenure at Bristol Myers Squibb company (BMS)™. “I am excited to contribute to the future direction and success of OBI Pharma as a potential leading cancer therapeutics biopharma company. I am impressed with the dedication and accomplishments of the organization to date. Additionally, with OBI’s innovative cancer pipeline under clinical trials to address unmet medical needs, it is an exciting time to join the organization,” stated Dr. Wang. Dr. Wang will report to Yun Yen, M.D, OBI Pharma’s Chairman of the Board. Prior to joining OBI Pharma, she was Vice President, Head of Global Regulatory Sciences Oncology. Additionally, she has held executive and senior management roles of increasing responsibilities as Interim Head of R&D and Regulatory in China, US and International Regulatory Strategy, Global Product Labeling, Medical Communications, and Research Discovery. Dr. Wang has received the following degrees: Ph.D. and M.S. degrees at the University of Notre Dame (South Bend, IN) and B.S. degree at Fu-Jen University (Taipei, Taiwan). She also received postdoctoral training in cancer biology at The Cold Spring Harbor Laboratory (Cold Spring Harbor, NY). She has won numerous awards and authored numerous scientific publications during her career. About OBI Pharma OBI Pharma, Inc., is a Taiwanese biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for important unmet medical needs against promising cancer targets such as the Globo series of glycosphingolipids (including Globo H and SSEA-4), AKR1C3, Trop-2, and others. The company’s novel first-in-class immuno-oncology portfolio targeting Globo H includes: two Globo H active immunotherapy vaccines, Adagloxad Simolenin (formerly OBI-822) and OBI 833; the Globo H antibody-drug conjugate (ADC) OBI-999, and the Globo H CAR T-cell therapeutic OBI-R007. OBI’s pipeline also includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme, and the novel next generation Trop-2 ADC, R992, which is designed to target 1st generation Trop-2-ADC resistant cancers. Additional information can be found at Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau. COMPANY CONTACT: Kevin Poulos OBI Pharma USA, Inc. 1.619.537.7698 Ext. 102 kpoulos@obipharmausa.com

高管变更免疫疗法抗体药物偶联物

2022-12-26

·蒲公英Ouryao

国抽不合格、辅仁防疫药品甘肃省被暂停交易！

转自：甘肃公共资源中心整理：wangxinglai20042022年12月16日，甘肃公共资源中心发布通知，因国家抽检产品不符合规定，按照《国家药监局关于8批次药品不符合规定的通告》（2022年第57号）要求，即日起暂停辅仁药业集团有限公司清热解毒口服液交易资格。通知原文各医疗机构、相关企业：按照《国家药监局关于8批次药品不符合规定的通告》（2022年第57号）要求，即日起暂停我省甘肃省国家医疗保障信息平台药品和医用耗材招采管理子系统中辅仁药业集团有限公司清热解毒口服液交易资格，请医疗机构选择其他生产企业该药品采购。联系电话：0931-2909268（17339814899）产品信息如下：注册证号：国药准字Z20033180规格10毫升*10支平台交易流水号：606501生产企业：辅仁药业集团有限公司生产地址：河南省鹿邑县产业集聚区同源路1号药品上市许可持有人：河南同源制药有限公司更多关于本次产品抽检不合格信息请关注：【国抽】辅仁、好医生等知名药企抗疫推荐用药不合格质量公告原文经苏州市药品检验检测研究中心等4家药品检验机构检验，标示为辅仁药业集团有限公司等6家企业生产的清热解毒口服液等8批次药品不符合规定。现将相关情况通告如下：一、经苏州市药品检验检测研究中心检验，标示为辅仁药业集团有限公司、江西钟山药业有限责任公司、好医生药业集团有限公司生产的4批次清热解毒口服液检出高于限量值的灰毡毛忍冬皂苷乙。二、对上述不符合规定药品，药品监督管理部门已要求相关企业和单位采取暂停销售使用、召回等风险控制措施，对不符合规定原因开展调查并切实进行整改。三、国家药品监督管理局要求相关省级药品监督管理部门依据《中华人民共和国药品管理法》，组织对上述企业和单位存在的涉嫌违法行为立案调查，并按规定公开查处结果。

带量采购

2022-12-14

·蒲公英Ouryao

【国抽】辅仁、好医生等知名药企抗疫推荐用药不合格

转自：国家药监局整理：wangxinglai20042022年12月14日，国家药监局发布了药品质量抽查检验结果通告（2022年第57号），本期抽检共涉及6家企业生产的8批次药品不符合规定，其中辅仁药业集团有限公司、江西钟山药业有限责任公司、好医生药业集团有限公司生产的4批次清热解毒口服液经抽检不符合规引人注意。重点内容分析辅仁药业集团有限公司、江西钟山药业有限责任公司、好医生药业集团有限公司生产的4批次清热解毒口服液经抽检不符合规定，这里边深度信息小编整理了下如下：常规品种、多年生产品种、多家企业均出现问题那证明这在业内是常态情况，换句通俗的话说，这四位可能是惯犯、其他同伙可能在路上；中检院发布了《清热解毒口服液中灰毡毛忍冬皂苷乙检查项》补充检验方法，2022-02-10生效，主要内容如下：那么什么是灰毡毛忍冬皂苷乙呢？【山银花】本品按干燥品计算，含绿原酸（C16H18O9）不得少于2.0%，含灰毡毛忍冬皂苷乙（C65H106O32）和川续断皂苷乙（C53H86O22）的总量不得少于5.0%。这意味着以山银花冒充金银花或金银花中掺杂山银花，看到这我觉得上边的几位惯犯可能是被供应商给坑了，因为金银花药材标准中确实没找到灰毡毛忍冬皂苷乙限制检测要求；但是转念一想不对，产品出厂是需要按照补充检验方法进行检测的，难道是一药难求铤而走险？小编寄语：清热解毒口服液可是属于抗疫属性产品，很多地方推荐储备用药也包括其中，最后如果摊上一个生产假劣抗疫药品，这罪名可就大了去，对于那些正在加班加点生产的企业，要时刻警醒这暴力后的雷霆之击；抗疫系列药品目前紧俏，但是要知道风险与收益是正比的，如果想以次充好、或以假乱真那后果可是致命的，发抗疫财无异于发国难财啊；最后说明以上内容纯属小编个人猜测和近期囤药、抢药的感想，并无具体后针对性；质量公告原文经苏州市药品检验检测研究中心等4家药品检验机构检验，标示为辅仁药业集团有限公司等6家企业生产的清热解毒口服液等8批次药品不符合规定。现将相关情况通告如下：一、经苏州市药品检验检测研究中心检验，标示为辅仁药业集团有限公司、江西钟山药业有限责任公司、好医生药业集团有限公司生产的4批次清热解毒口服液检出高于限量值的灰毡毛忍冬皂苷乙。经深圳市药品检验研究院检验，标示为安徽鸿坤药业有限公司生产的1批次金银花不符合规定，不符合规定项目为含量测定。经安徽省食品药品检验研究院检验，标示为安徽援康中药饮片股份有限公司生产和抽取自安徽省春源大药房有限公司的2批次桃仁不符合规定，不符合规定项目包括性状、显微鉴别。经甘肃省药品检验研究院检验，标示为安徽方氏制药有限公司生产的1批次茜草不符合规定，不符合规定项目包括性状、显微鉴别。二、对上述不符合规定药品，药品监督管理部门已要求相关企业和单位采取暂停销售使用、召回等风险控制措施，对不符合规定原因开展调查并切实进行整改。三、国家药品监督管理局要求相关省级药品监督管理部门依据《中华人民共和国药品管理法》，组织对上述企业和单位存在的涉嫌违法行为立案调查，并按规定公开查处结果。扫描二维码查看原文往期信息 01 广西药监局广西抽查检验结果共计涉及22批次产品，其中：制剂品种：花蛇解痒胶囊、祛风止痛丸、坤宝丸、五子衍宗丸、风热感冒胶囊、抗病毒口服液；中药饮片：芦荟、海藻、防己、紫石英、甘松、当归、天葵子、谷精草、山豆根、龙骨、茜草、百部、旋覆花；制剂品种抽检不符合项目中全部涉及装量差异值得关注；【点评】一直以来，如何保证药品每一最小剂量单位装量准确且全部符合规定归于药企来说都是难题，尤其是存在引湿性的固体制剂，受水分增长影响常会出现装量不合格，小编见过使用检重秤对胶囊剂、片剂逐粒称量的，也见过在线红外扫描的；不知道大家都是用什么方法来控制装量的，欢迎留言交流；为了加强药品管理，保证药品质量，保障公众用药安全，根据年度抽检计划和日常监管需要，我局组织对全区药品生产、经营和使用单位开展了药品质量抽查检验。扫描二维码查看原文具体信息详见下图：我局已组织相关监管部门对公告不符合规定产品采取控制措施，并依法查处。特此公告。02 河北药监局按照《2022年河北省药品监督抽检计划》，河北省各级药品监督管理部门和药品检验机构对全省药品生产企业、经营企业和使用单位的药品质量进行了抽查检验。现将药品监督抽验中不符合标准规定药品予以公告：1、标示安国市深豪药业有限公司生产的防己(批号C149211001）经沧州市食品药品检验所检验，【性状】项不符合规定（被抽样单位为沧州市南皮阳光医院）。2、标示四川金岁方药业有限公司生产的琥珀(批号211001）经张家口市食品药品检验中心检验，【性状】项不符合规定（被抽样单位为张家口市万全区中医院）。扫描二维码查看原文对本公告中不符合标准规定的药品，相关药品监督管理部门已依法采取查封扣押等控制措施。自本公告发布之日起，请有关药品监督管理部门依据《中华人民共和国药品管理法》有关规定，对上述药品生产企业生产销售不合格药品的违法行为进行立案调查，并采取必要风险控制措施，于三个月内公开对生产销售不符合标准规定药品相关企业或单位的处理结果。公告中涉嫌假冒的药品，要查清相关来源渠道，涉嫌构成犯罪的，移送公安部门依法查处。相关情况及时报告河北省药品监督管理局稽查处。特此公告

100 项与辅仁大学相关的药物交易

登录后查看更多信息

100 项与辅仁大学相关的转化医学

登录后查看更多信息